AllSci News
Ohio State University develops exosome-based RNA nanotechnology to silence mutant KRAS in mCRC
Ohio State University has received a USD 1.43 million NCI R01 grant to develop an exosome-based RNA nanotechnology platform targeting mutant KRAS in...
FDA grants accelerated approval to Vera’s Trutakna, first dual BAFF/APRIL inhibitor for IgA nephropathy
The US FDA has granted accelerated approval to Trutakna (atacicept-vymj) for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk…
OTR Therapeutics partners with LG Chem to channel Chinese oncology assets into global development
Shanghai-based OTR Therapeutics and South Korea-based LG Chem (KRX: 051910) have announced a multi-program strategic collaboration to identify, evaluate, and advance oncology…
Seres' biotherapeutic resolves checkpoint inhibitor colitis without systemic immunosuppression
Cambridge, Massachusetts-based Seres Therapeutics (Nasdaq: MCRB) reported early clinical data suggesting that SER-155, its oral live biotherapeutic, may...
UroGen's UGN-501 oncolytic virus gains FDA clearance for non-muscle invasive bladder cancer trial
UroGen Pharma (Nasdaq: URGN) announced on July 8, 2026 that the US FDA cleared its Investigational New Drug application for UGN-501, an oncolytic virus...
Rejuvenation Technologies backed with grant to move TERT mRNA into clinic for alcoholic hepatitis
Rejuvenation Technologies, Inc., a Mountain View, California-based biotechnology company, has received a USD 2.06 million NIAAA SBIR Commercialization...
Immunome advances varegacestat toward approval as second oral option for desmoid tumors
The US FDA has accepted for review the New Drug Application submitted by Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) for varegacestat (formerly...
Sino Bio expands GSK partnership into respiratory, securing China rights to USD 4.5b inhaler franchise
GSK is extending its Sino Bio GSK collaboration into respiratory medicine, handing China commercialization rights for two of its highest-revenue inhaled...
AstraZeneca secures ex-China rights to Sino Bio's TQC3721 in USD 2.1b respiratory deal
AstraZeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth USD 200 million upfront and up to USD 2.1...
Xiaflex wins first-ever FDA approval pathway for plantar fibromatosis with Phase III success
Keenova Therapeutics has reported that collagenase clostridium histolyticum (Xiaflex) met its primary endpoint in a pivotal Phase III trial for plantar...
Bayer aims to accelerate clinical trials through first academic medical center alliance in Colorado
Bayer announced a clinical trial collaboration alliance with the University of Colorado Anschutz Medical Campus, UCHealth, and Children’s Hospital Colorado, marking the…
FDA bestows BTD on Merck KGaA’s enpatoran for lupus skin manifestations
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US and Canada, announced that the US FDA has granted…
Evogene pairs ChemPass AI with Tel Aviv University to accelerate academic drug discovery pipeline
Israel-based computational chemistry company Evogene Ltd. (Nasdaq: EVGN) and the Blavatnik Center for Drug Discovery (BCDD) at Tel Aviv University have announced…
Chicago Uni engineers bacteria to deliver immunotherapy directly to pancreatic tumors
The University of Chicago has received a USD 1.75 million National Cancer Institute R01 award to develop genetically engineered Bifidobacterium as a...
Helix secures AstraZeneca partnership to power drug discovery with US genomic data
AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and...
The AllSci Brief
Systematic R&D and deal news. Daily.